Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts-Reference-Cited by-同舟云学术

Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts

Published:2016-10-03 Issue:3 Volume:176 Page:643-649
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

García-Doval I.¹²,Hernández M.V.³,Vanaclocha F.⁴,Sellas A.⁵,de la Cueva P.⁶,Montero D.⁷,

Affiliation:

1. Research Unit; Fundación Academia Española de Dermatología y Venereología; Madrid Spain

2. Dermatology Department; Complexo Hospitalario Universitario de Vigo; Vigo Spain

3. Rheumatology Department; Hospital Clinic; Barcelona Spain

4. Dermatology Department; Hospital Universitario 12 de Octubre; Madrid Spain

5. Rheumatology Department; Hospital Universitario Vall d'Hebron; Barcelona Spain

6. Dermatology Department; Hospital Universitario Infanta Leonor; Madrid Spain

7. Division of Pharmacoepidemiology and Pharmacovigilance; Agencia Española del Medicamento y Productos Sanitarios (AEMPS); Madrid Spain

Funder

Spanish Medicines and Health Products Agency (Agencia Española del Medicamento y Productos Sanitarios)

Abbott Fund

Pfizer

Meso Scale Diagnostics

Janssen Research and Development

Fundacion Española de Reumatología

Roche

Schering-Plough

Bristol-Myers Squibb

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.14776/fullpdf

Reference24 articles.

1. TNF-mediated inflammatory disease;Bradley;J Pathol,2008

2. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls;Silva;Immunotherapy,2010

3. Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders;Calamia;Adv Exp Med Biol,2003

4. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0;Carmona;Rheumatology (Oxford),2011

5. Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational?;Baeten;Ann Rheum Dis,2010

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological disorders following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis;Expert Opinion on Drug Safety;2024-05-23

2. Systemic immunotherapies;Procedures in Cosmetic Dermatology: Hair Restoration;2024

3. The predictive accuracy of cardiovascular disease risk prediction tools in inflammatory arthritis and psoriasis: an observational validation study using the Clinical Practice Research Datalink;Rheumatology;2023-11-15

4. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry;British Journal of Dermatology;2023-10-17

5. Role of chemokine receptor 2 in rheumatoid arthritis: A research update;International Immunopharmacology;2023-03